# Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia

> **NCT04676971** · PHASE2 · COMPLETED · sponsor: **ImmuneMed, Inc.** · enrollment: 115 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** hzVSF-v13
- **DRUG:** Placebo (Normal saline solution)

## Key facts

- **NCT ID:** NCT04676971
- **Lead sponsor:** ImmuneMed, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-11
- **Primary completion:** 2021-08-29
- **Final completion:** 2021-10-28
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2021-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04676971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04676971, "Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04676971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*